Preliminary schedule

1. Afternoon Scientific session 13:30-18:00

13:30 Opening registration 

14:00 Welcome and opening of the symposium 

14:10 Highly pathogenic avian influenza H5 virus as a continuing pandemic threat  

        Prof. Ron Foucher - Erasmus MC department of Viroscience

14:40 Organisation of NRC: Battery of tests available at NRC and unresolved maxipanels 

        Prof. dr. Emmanuel André - Laboratoriumgeneeskunde, UZ Leuven 

15:00 SARI Surveillance 

         Sr. Yinthe Dockx - Sciensano 

15:20 Alternative/complementary surveillance 

         To be communicated - Sciensano 

15:40 Coffee break  

16:10 Mycoplasma pneumoniae and other respiratory bacteria

        Prof. dr. Pharm. biol. Veerle Matheeussen -  UZA 

16:35 Position of the virus bank: viral typing, phenotyping, whole genome sequencing 

        Prof. Peter Delputte - ReViRAnt, UAntwerpen 

17:00 ​Pandemic preparedness: The importance of Controlled Human Infection (CHIM) studies for evaluating respiratory viral vaccines and therapeutics 

        Sr. Bart Van Meerbergen - Vaccinopolis

17:25 Models and tools for research on respiratory viral infections

        dr. Koert Stittelaar - KULeuven 

2. Registration evening session and walking dinner 18:00-19:00

3. Evening policy and clinical session 19:00-20:55

19:00 Opening evening session 

19:10 Policy talk 

        To be communicated 

19:25 Wrap up of winter season 

        MD Yves Lafort - Sciensano 

19:40 The AS01E-adjuvanted RSVPreF3 vaccine exhibits broad efficacy against diverse RSV strains

        dr. Lucile Warter - GSK 

19:55 Efficacy, Effectiveness and Clinical Development Programme of RSVpreF 

        MD Machteld De Bock and dr. Keliane Liberman - Pfizer 

20:10 Sanofi as partner in RSV prevention

        MD Patrick Dhont - Sanofi 

20:25 To be communicated 

        dr. Chloé Abels - MSD 

20:40 Lessons learned from the RAG

        To be communicated 

4. End of symposium and reception - 20:55 - 21:55

Note: This is a preliminary schedule. The final schedule, including allocated Q&A time, will be adjusted based on speaker confirmations and may include extended Q&A sessions. Any changes will be communicated promptly.